Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner
VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it has received an additional order from Tabletz LLC. Tabletz LLC received a purchase order from one of its distribution partners in Japan and has placed an additional order with the Company for three-tab Tabletz sticks, including all 3 flavours - Mint, Lemon and Berry.» Mehr auf accesswire.com
NeutriSci Arranges Strategic Financing with Tabletz and Exercise of Warrants
VANCOUVER, BC / ACCESSWIRE / September 10, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products, licencing IP, and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it has arranged a non-brokered private placement (the "Placement") and the exercise of 4,900,000 warrants, for total combined proceeds of $276,550. The Placement, which is being completed with a principal of the Company's distribution partner in Japan, Tabletz LLC, consists of 210,333 units (the "Units") of the Company at a price of $0.15 per Unit.» Mehr auf accesswire.com
Neutrisci Provides Update on Tabletz Developments
VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to provide an update on previously announced projects. Biople: After receiving an exclusive first-to-market period from Tabletz LLC, Biople's sales of Tabletz ranked #2 in product sales in Biople stores and online.» Mehr auf accesswire.com

Unternehmenszahlen

Im letzten Jahr hatte NeutriSci International einen Umsatz von 314,48k€ und ein Nettoeinkommen von −529,48k€

(EUR)	2022	YOY
Umsatz	+314,48k	458,75%
Bruttoeinkommen	−29,82k	108,60%
Nettoeinkommen	−529,48k	51,60%
EBITDA	−503,88k	52,54%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+736,46 Mio€
Anzahl Aktien	651,87 Mrd
52 Wochen-Hoch/Tief	+0,00113€ - +0,00113€
Dividenden	Nein
Beta	-0,47
KGV (PE Ratio)	−1,08
KGWV (PEG Ratio)	−0,01
KBV (PB Ratio)	−1,35
KUV (PS Ratio)	+1,95

Unternehmensprofil

NeutriSci International Inc. entwickelt, vermarktet und vertreibt nutrazeutische Produkte in Kanada, den Vereinigten Staaten, Europa, Asien und Südamerika. Das Unternehmen bietet Neuenergy an, eine Energietablette, die für eine verbesserte Konzentration und geistige Klarheit sorgen soll. Das Unternehmen vertreibt seine Produkte über ein Vertriebsnetz von Einzelhandels- und Online-Kanälen. NeutriSci International Inc. hat Partnerschaften mit LaSanta Botanicals, Nutritional High und Naturally Splendid. NeutriSci International Inc. wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.